BIOCQ — Biocept Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$4.46m
- $25.86m
U.S. STOCKS ON THE MOVE-Overstock.com, Biocept, Birkenstock
Biocept slumps after filing for bankruptcy protection
Brief: Biocept CEO Antonino Morales Resigns
U.S. STOCKS ON THE MOVE-Albemarle, Novavax, WeWork
Brief: Enrollment Completed In The Feasibility Phase Of The Foresee Clinical Trial With Biocept’S Cnside Assay
U.S. STOCKS ON THE MOVE-Asbury, natgas firms, energy firms
Brief: Biocept Signs CNSide Licensing Agreement With Plus Therapeutics
Biocept, Plus Therapeutics rises on licensing deal for cancer treatment
Brief: Biocept Announces The Passing Of Board Chair M. Faye Wilson
Brief: Biocept Names Antonino Morales As President And Chief Executive Officer
Brief: Biocept Announces Pricing Of $5 mln Underwritten Public Offering
Biocept plummets on 1-for-30 reverse stock split
Brief: Biocept Announces One-For-Thirty Reverse Stock Split
Brief: Biocept Inc Stockholders’ Equity As Of March 31 Was $2.4 Million
Brief: Biocept Reports First Quarter 2023 Financial Results
Brief: Biocept Inc Says Lowering Headcount By More Than 40% From Our Pre-Covid-19 Testing Level
Brief: Biocept- On April 14, Determined Financial Statements For Qtrs Ended March 31, 2022, June 30, 2022 And Sept 30, 2022 Should No Longer Be Relied Upon
Biocept Inc expected to post a loss of 22 cents a share - Earnings Preview
Brief: Enrollment Begins In Foresee Clinical Trial Using Biocept’S Cnside™ To Evaluate Patients With Leptomeningeal Metastases